Your browser doesn't support javascript.
loading
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Meininger, Vincent; Pradat, Pierre-François; Corse, Andrea; Al-Sarraj, Safa; Rix Brooks, Benjamin; Caress, James B; Cudkowicz, Merit; Kolb, Stephen J; Lange, Dale; Leigh, P Nigel; Meyer, Thomas; Milleri, Stefano; Morrison, Karen E; Orrell, Richard W; Peters, Gary; Rothstein, Jeffrey D; Shefner, Jeremy; Lavrov, Arseniy; Williams, Nicola; Overend, Phil; Price, Jeffrey; Bates, Stewart; Bullman, Jonathan; Krull, David; Berges, Alienor; Abila, Bams; Meno-Tetang, Guy; Wurthner, Jens.
Afiliación
  • Meininger V; Département des Maladies du Système Nerveux, Assistance Publique - Hôpitaux de Paris, Centre de Référence Maladies Rares SLA, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre-et-Marie-Curie, Paris, France.
  • Pradat PF; Département des Maladies du Système Nerveux, Assistance Publique - Hôpitaux de Paris, Centre de Référence Maladies Rares SLA, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre-et-Marie-Curie, Paris, France; Unité Mixte de Recherche-678, Institut National de la Santé et de la Recherche Médicale
  • Corse A; Neuromuscular Pathology Lab, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
  • Al-Sarraj S; Department of Clinical Neuropathology, Kings College Hospital/Kings College London, London, United Kingdom.
  • Rix Brooks B; Carolinas Neuromuscular/Amyotrophic Lateral Sclerosis-Muscular Dystrophy Association Center, Department of Neurology, Carolinas Medical Center and University of North Carolina School of Medicine-Charlotte Campus, Charlotte, North Carolina, United States of America.
  • Caress JB; Wake Forest School of Medicine, M Reynolds Tower, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America.
  • Cudkowicz M; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Kolb SJ; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America.
  • Lange D; Department of Neurology, Weill Cornell School of Medicine, New York, New York, United States of America.
  • Leigh PN; Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, Falmer, Sussex, United Kingdom.
  • Meyer T; Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Milleri S; Centro Ricerche Cliniche, University Hospital G.B. Rossi, Verona, Italy.
  • Morrison KE; School of Clinical and Experimental Medicine, University of Birmingham and Neurosciences Department, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Orrell RW; Department of Clinical Neuroscience, Institute of Neurology, University College London, London, United Kingdom; Department of Neurology, Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Peters G; GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.
  • Rothstein JD; Brain Science Institute, Johns Hopkins University, Department of Neurology, Baltimore, Maryland, United States of America.
  • Shefner J; Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, United States of America.
  • Lavrov A; Neurosciences Therapy Area Unit, Medicines Discovery and Development, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom.
  • Williams N; Clinical Statistics, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
  • Overend P; Clinical Statistics, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
  • Price J; Clinical Pharmacology, Science and Study Operations, BioPharm and Infectious Diseases, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
  • Bates S; BioPharm Translational Medicine, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
  • Bullman J; Clinical Pharmacology Modelling & Simulation (Neurosciences), GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
  • Krull D; Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America.
  • Berges A; Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom.
  • Abila B; BioPharm Translational Medicine, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
  • Meno-Tetang G; Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom.
  • Wurthner J; Oncology Translational Medicine, Novartis Basel, Switzerland.
PLoS One ; 9(5): e97803, 2014.
Article en En | MEDLINE | ID: mdl-24841795
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Esclerosis Amiotrófica Lateral / Anticuerpos Monoclonales / Proteínas de la Mielina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Esclerosis Amiotrófica Lateral / Anticuerpos Monoclonales / Proteínas de la Mielina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos